Science‐based innovation as systematic risk‐taking: The case of new drug development

Abstract

Purpose

Research on innovation and knowledge management practice would benefit from examining science‐based innovation work, that is, innovations derived from the ability to exploit scientific know‐how, in greater detail. While much engineering innovation work may be predetermined through rational breakdown analysis, there is always a factor of chance and luck in scientific work. Scientific work is never linear and predictable but must always be envisaged as the outcome of a combination of rule‐governed activities and a certain degree of unconditioned discoveries. The purpose of this paper is to report on how practicing laboratory researchers in a major pharmaceutical company regard their innovation work as being what is always of necessity inherently indeterminate and therefore put demands on top management to allow for a reasonable amount of risk‐taking.

Design/methodology/approach

Case study methodology based on interviews with 36 laboratory scientists and managers in a major pharmaceutical company.

Findings

The paper concludes that innovation research and knowledge management studies need to regard science‐based innovation as a specific form of innovation not wholly capable of being managed through rationalist management control systems.

Originality/value

The paper bridges studies of innovation work in pharmaceutical industry with the perception of risk‐taking among the practicing researchers.

Citation

Styhre, A. (2006), "Science‐based innovation as systematic risk‐taking: The case of new drug development", European Journal of Innovation Management, Vol. 9 No. 3, pp. 300-311. https://doi.org/10.1108/14601060610678167